Cardiac Marker Testing Market Share, Size, Trends, Industry Analysis Report, By Product (Reagents and Kits and Instruments); By Biomarker Type; By End-User; By Region; Segment Forecast, 2023-2032

Cardiac Marker Testing Market Share, Size, Trends, Industry Analysis Report, By Product (Reagents and Kits and Instruments); By Biomarker Type; By End-User; By Region; Segment Forecast, 2023-2032

The global cardiac marker testing market size is expected to reach USD 9.73 billion by 2032, according to a new study by Polaris Market Research. The report “Cardiac Marker Testing Market Share, Size, Trends, Industry Analysis Report, By Product (Reagents and Kits and Instruments); By Biomarker Type; By End-User; By Region; Segment Forecast, 2023-2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Rapid increase in the number of cardiovascular disease patients globally in the emergency departments (EDs), the rising demand and adoption for several cardio biomarkers test like POCT, are prominent factors propelling the global market growth. Moreover, new players are continuously entering into the market with tests in order to generate maximum revenues and established players are focusing on developing and expanding their portfolio by investing in R&D activities, that are further anticipated to create growth opportunities. For instance, in January 2023, Cipla, introduced its new testing devices named ‘Cippoint’, a CE IVD-approved point-of-care testing device that offers testing for diabetes, infectious diseases, thyroid function, inflammation, and metabolic markers.

Moreover, the recent advances in the cardiac markers from the commercial devices to emerging technologies such as cardiac troponin and natriuretic peptides and Point-Of-Care immunoassays with improved specificity and reliability by enabling the multiplexing through the numerous molecular targets in single assays. The rising consumption of several types of unhealthy food products among millennials resulting in high number of angina pectoris cases, thus to cater the surging demand from these patient pool, adoption of cardiac biomarkers will increase rapidly.

With the drastic increase in the prevalence for cancer diseases and various other disorders and governments are heavily investing their time and money towards the development of their healthcare systems and access to advanced cardiac markers testing devices. For instance, according to a new study done by American College of Cardiology, researchers found that ApoB testing might help in the identification of patients who may still be at the high risk of cardiovascular without having normal LDL cholesterol levels.

Cardiac Marker Testing Market Report Highlights

Reagents and kits segment accounted for major global market share in 2022, on account on increasing adoption of the cardiac biomarker tests

Troponin I and T segment held the significant market revenue share in 2022, mainly due increasing demand for these devices to diagnose acute myocardial infraction

Point-of-care facilities segment is projected to grow at a highest CAGR over the study period, that is highly attributable to its growing utilization among major healthcare service providers

North America region dominated the global market in 2022, owing to high spending on healthcare infrastructure and quick adoption of advanced cardiac biomarkers in countries like US and Canada

The global key market players include Bio-Rad Laboratories, Thermo Fisher Scientific, Abbott Laboratories, Danaher Corporation, Medtronic PLC; Stryker Corporation; Zimmer-Biomet Holdings, Inc.; DePuy Synthes; Smith and Nephew PLC; Aesculap Implant Systems, LLC; Conmed Corporation; Donjoy, Inc.; NuVasive, Inc. and Roche

Polaris Market Research has segmented the cardiac marker testing market report based on product, biomarker type, end-user, and region:

Cardiac Marker Testing, Product Outlook (Revenue - USD Billion, 2018 - 2030)

Reagents and Kits

Instruments

Cardiac Marker Testing, Biomarker Type Outlook (Revenue - USD Billion, 2018 - 2030)

Troponin I and T

Creatine Kinase-MB (CK-MB)

Natriuretic Peptide

Myoglobin

High Sensitivity C-Reactive Protein

Other Cardiac Biomarkers

Cardiac Marker Testing, End-User Outlook (Revenue - USD Billion, 2018 - 2030)

Laboratory Testing Facilities

Point-Of-Care Testing Facilities

Academic Institutions

Cardiac Marker Testing, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa